))
Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Manage episode 525666059 series 3693272
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Host: Pavani Chalasani, MD, MPH
Guest: Timothy Yap, MBBS, PhD, FRCP
Early findings from the PETRA study suggest that combining saruparib with camizestrant may offer added clinical benefit in ER+/HER2– advanced breast cancer, particularly in patients with BRCA or PALB2 mutations. Tune in to hear from Dr. Pavani Chalasani and Dr. Timothy Yap as they discuss this encouraging new data on tolerability and antitumor activity. Dr. Yap is the Ransom Horne, Jr. Endowed Professor for Cancer Research, Vice President and Head of Clinical Development in the Therapeutic Discovery Division, and a professor in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. He recently presented this research at the 2025 San Antonio Breast Cancer Symposium.
…
continue reading
Guest: Timothy Yap, MBBS, PhD, FRCP
Early findings from the PETRA study suggest that combining saruparib with camizestrant may offer added clinical benefit in ER+/HER2– advanced breast cancer, particularly in patients with BRCA or PALB2 mutations. Tune in to hear from Dr. Pavani Chalasani and Dr. Timothy Yap as they discuss this encouraging new data on tolerability and antitumor activity. Dr. Yap is the Ransom Horne, Jr. Endowed Professor for Cancer Research, Vice President and Head of Clinical Development in the Therapeutic Discovery Division, and a professor in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. He recently presented this research at the 2025 San Antonio Breast Cancer Symposium.
299 episodes
Share
